|Mr. John F. Crowley||Chairman & CEO||1.9M||N/A||1967|
|Mr. Bradley L. Campbell M.B.A.||Pres, COO & Director||812.03k||185.55k||1976|
|Ms. Ellen S. Rosenberg||Chief Legal Officer & Corp. Sec.||653.34k||N/A||1963|
|Dr. Jay A. Barth||Chief Medical Officer||668.71k||537.04k||1964|
|Ms. Daphne E. Quimi||Chief Financial Officer||N/A||N/A||1966|
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 1/2 (ATB200-02) and Phase 3 (ATB200-03) clinical studies for Pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize Galafold as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies; and a strategic manufacturing agreement with Catalent Biologics. The company also has a strategic manufacturing collaboration with Thermo Fisher Scientific for conducting preclinical and clinical-stage gene therapy programs for CLN6, CLN3, and other Batten disease programs. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Amicus Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 7; Compensation: 4.